<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 10-Apr| 06:00 - 07:00 AM | Best Practices in Establishing Value in Laboratory Testing | Bio-Rad Unity as a Solution for Molecular Quality Control Data Management | Duane W. Newton, PhD, D(ABMM), FIDSA  
Director, Clinical Microbiology Laboratory, Associate Director,  
Division of Clinical Pathology, Professor of Pathology, University of Michigan |
| 10-Apr| 06:00 - 07:00 AM | Disruptive Molecular Technologies | Keynote Presentation: Nucleic Acid Detection with CRISPR Diagnostics | Omar Abudayyeh, PhD  
MIT McGovern Institute Fellow  
Jonathan Gootenberg, PhD  
MIT McGovern Institute Fellow, Massachusetts Institute of Technology |
| 10-Apr| 07:30 - 08:30 AM | Best Practices in Establishing Value in Laboratory Testing | Keynote Presentation: Clinical Lab 2.0 - How Laboratories Can Thrive in a Value Based Care System | Michael Crossey, MD, PhD  
Chief Executive Officer and Chief Medical Officer, TriCore Reference Laboratories |
| 10-Apr| 09:00 - 10:00 AM | Disruptive Molecular Technologies | CRISPR Proteins: Enabling the Next-Generation of Molecular Diagnostics | James Broughton  
Senior Scientist, Mammoth Biosciences |
| 10-Apr| 09:00 - 10:00 AM | Disruptive Molecular Technologies | Novel Applications of Molecular Diagnostics in Infectious Diseases | Esther Babady, PhD  
Director of Clinical Operations, Microbiology Service, Associate Attending Microbiologist, Departments of Medicine and Laboratory Medicine, Memorial Sloan Kettering Cancer Center |
| 10-Apr| 09:00 - 10:00 AM | Best Practices in Establishing Value in Laboratory Testing | Validation and Implementation of Quantitative Molecular Assays | Morgan A. Pence, PhD, D(ABMM)  
Director, Clinical and Molecular Microbiology, Cook Children's Medical Center |
| 10-Apr| 10:30 - 11:30 AM | Disruptive Molecular Technologies | A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations | Anika Joecker, PhD  
Associate Director Global Product Management NGS, QIAGEN  
Jennifer Poitras, PhD  
Principal Genome Scientist, Bioinformatics - Genetic Disease , QIAGEN |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Presentation Title</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 10-Apr | 10:30 AM - 11:30 AM | Digital Diagnostics and Artificial Intelligence      | Better Knowledge, Better Care: Precision Medicine for Any Cancer, Any Assay, on Your Platform | Sheryl Elkin, PhD  
Chief Scientific Officer, N-of-One, A QIAGEN Company  
Dan Richards, PhD  
Vice President, Biomedical Informatics, QIAGEN |
| 10-Apr | 10:30 AM - 11:30 AM | Disruptive Molecular Technologies                    | CRISPR-Chip: Detection of Unamplified Target Genes via CRISPR/Cas9 Immobilized on a Graphene Biosensors | Kiana Aran, PhD  
Co-Founder, Nanosens, Assistant Professor of Biomedical Sciences at Keck Graduate Institute, Visiting Assistant Professor at UC Berkeley |
| 10-Apr | 12:00 PM - 01:00 PM  | Best Practices in Establishing Value in Laboratory Testing | Best Practices for Implementing NGS and Positioning for Future Growth: Perspectives from 2 Labs | Tony Magliocco, MD  
Executive Director of the Advanced Diagnostic Laboratories, Moffitt Cancer Center  
Keith Gligorich, PhD  
Laboratory Operations Director, Navican Precision Cancer Care |
| 10-Apr | 12:00 PM - 01:00 PM  | Disruptive Molecular Technologies                    | Digital Biosensors and the Internet of Biology                                      | Brett Goldsmith, PhD  
CTO, Cardea |
| 10-Apr | 12:00 PM - 01:00 PM  | Disruptive Molecular Technologies                    | Transforming Oncology with ctDNA+ctRNA Liquid Biopsy Solutions                       | Shidong Jia, MD, PhD  
CEO, Predicine |
| 10-Apr | 01:30 PM - 02:30 PM | Disruptive Molecular Technologies                    | Detection and Interpretation of Complex Myeloid Leukemia Mutations                   | Véronique Laloux, PhD  
Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN  
Beate Litzenburger, PhD  
Product Owner of QIAGEN Clinical Insight (QCI™) Intepret |
| 10-Apr | 01:30 PM - 02:30 PM | Best Practices in Establishing Value in Laboratory Testing | Laboratory Medicine Beyond The Box: Value Based Health Care & Diagnostic Evidence     | Elizabeth Marlowe, PhD, D(ABMM)  
Global Director of Medical Affairs, Microbiology, Roche Molecular Systems  
Joanna Sickler, MPH, MBA  
Director of Medical Affairs, Point-of-Care, Roche Molecular Systems |
| 10-Apr | 01:30 PM - 02:30 PM | Best Practices in Establishing Value in Laboratory Testing | Tools & Processes for Making Evidence-Based Policy Decisions                          | Eugean Jiwanmall, MPH, MBA  
Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross |